Northwest Biotherapeutics AI Stock Analysis
Northwest Biotherapeutics (NBYB) AI Stock Analysis
Northwest Biotherapeutics
(Stuttgart:NBYB)
No summary available
Northwest Biotherapeutics (NBYB) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 287.23M
- Dividend Yield
- ―
- Average Volume (3M)
- 24.42K
- Price to Earnings (P/E)
- -6.8
- Beta (1Y)
- 0.93
- Revenue Growth
- 84.01%
- EPS Growth
- 62.78%
- Country
- Germany
- Employees
- 105
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Northwest Biotherapeutics Business Overview & Revenue Model
Company Description
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary t...
Northwest Biotherapeutics Risk Analysis
Northwest Biotherapeutics disclosed 38 risk factors in its most recent earnings report. Northwest Biotherapeutics reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksNorthwest Biotherapeutics Peers Comparison
Overall Rating
INO55Neutral
ANIX49Neutral
PDSB44Neutral
GNLX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| INO | 55Neutral | $149.93M | -1.85 | 0.84% | ― | 63.93% | 68.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ANIX | 49Neutral | $106.38M | -9.11 | -70.44% | ― | ― | 10.04% |
| PDSB | 44Neutral | $108.16M | -1.59 | -708.20% | ― | ― | 30.16% |
| GNLX | 41Neutral | $88.23M | -2.11 | -195.42% | ― | ― | -1.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:NBYB | Northwest Biotherapeutics | 0.14 | -0.06 | -30.69% | |
| INO | Inovio Pharmaceuticals | 1.48 | -0.47 | -24.36% | |
| PDSB | Pds Biotechnology | 1.02 | 0.18 | 20.71% | |
| ANIX | Anixa Biosciences | 2.78 | -1.61 | -36.67% | |
| GLSI | Greenwich Lifesciences, Inc. | 16.09 | 7.89 | 96.22% | |
| GNLX | Genelux Corp. | 1.88 | -3.63 | -65.88% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.